We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

110 hedge funds and large institutions have $854M invested in Revance Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 29

7% more call options, than puts

Call options by funds: $2.08M | Put options by funds: $1.94M

0% more funds holding

Funds holding: 110 → 110 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

11% less capital invested

Capital invested by funds: $957M → $854M (-$103M)

Holders
110
Holders Change
–
Holders Change %
0%
% of All Funds
2.51%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
13
Increased
33
Reduced
29
Closed
13
Calls
$2.08M
Puts
$1.94M
Net Calls
+$139K
Net Calls Change
-$607K

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$14.1M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$11.9M
3
AllianceBernstein
AllianceBernstein
Tennessee
+$9.3M
4
Capital International Investors
Capital International Investors
California
+$8.84M
5
BlackRock
BlackRock
New York
+$7.15M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$29.8M
2
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$16M
3
Millennium Management
Millennium Management
New York
-$12.3M
4
O
OppenheimerFunds
New York
-$6.93M
5
Capital World Investors
Capital World Investors
California
-$5.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
Principal Financial Group
26
Principal Financial Group
Iowa
$3.18M +$60.8K +2,236 +2%
Citadel Advisors
27
Citadel Advisors
Florida
$2.9M -$1.31M -48,028 -29%
EIM
28
Essex Investment Management
Massachusetts
$2.17M – – –
Allianz Asset Management
29
Allianz Asset Management
Germany
$2.12M +$172K +6,311 +8%
Federated Hermes
30
Federated Hermes
Pennsylvania
$2.08M +$100K +3,680 +5%
Goldman Sachs
31
Goldman Sachs
New York
$2.07M -$1.44M -52,872 -39%
Bank of America
32
Bank of America
North Carolina
$2.05M -$1.04M -38,157 -32%
USAA
33
United Services Automobile Association
Texas
$1.95M -$30.7K -1,130 -1%
TCM
34
Tekla Capital Management
Massachusetts
$1.94M – – –
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$1.88M +$2.06M +75,756 New
TCIM
36
TIAA CREF Investment Management
New York
$1.88M -$977K -35,935 -32%
AA
37
ALPS Advisors
Colorado
$1.62M +$325K +11,952 +22%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$1.62M -$348K -12,792 -16%
WRF
39
Waddell & Reed Financial
Kansas
$1.59M – – –
QI
40
QS Investors
New York
$1.57M – – –
TA
41
Teachers Advisors
New York
$1.56M +$74.5K +2,741 +5%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$1.51M +$745K +27,400 +82%
QOP
43
Quinn Opportunity Partners
Virginia
$1.46M +$695K +25,572 +77%
Swiss National Bank
44
Swiss National Bank
Switzerland
$1.27M – – –
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$1.25M -$462 -17 -0%
RCAMU
46
Rothschild & Co Asset Management US
Connecticut
$1.21M +$199K +7,299 +18%
PPA
47
Parametric Portfolio Associates
Washington
$1.16M +$256K +9,429 +25%
Los Angeles Capital Management
48
Los Angeles Capital Management
California
$1.11M +$46.5K +1,710 +4%
FMBTD
49
First Midwest Bank Trust Division
Illinois
$993K +$408K +14,986 +60%
Two Sigma Investments
50
Two Sigma Investments
New York
$970K -$2.9M -106,638 -73%
1
2
3 4 5

RVNC Hedge Fund Activity: Q3 2018 in Review

110 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2018, worth a combined $854M — down 11% from $957M a quarter earlier.

Fund positioning in RVNC was balanced in Q3 2018: 13 funds opened new positions, 13 closed out, 33 added to existing stakes and 29 trimmed.

The largest buyer was Bank of New York Mellon, adding an estimated $14.1M. The largest seller was Jennison Associates, cutting an estimated $29.8M.

  • 110 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $854M of Revance Therapeutics, Inc. stock for Q3 2018, down 11% quarter-over-quarter.
  • 13 funds opened new Revance Therapeutics, Inc. positions in Q3 2018 and 13 closed out, a net change of 0 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q3 2018 was Bank of New York Mellon, an estimated $14.1M added.
  • The largest Revance Therapeutics, Inc. seller in Q3 2018 was Jennison Associates, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2018.